The Use of Biologics During the COVID-19 Pandemic.
Dermatol Clin
; 39(4): 545-553, 2021 Oct.
Article
in English
| MEDLINE | ID: covidwho-1347570
ABSTRACT
During the coronavirus disease 2019 (COVID-19) pandemic, there has been considerable discussion regarding the use of biologics in patients with inflammatory skin conditions, such as psoriasis, hidradenitis suppurativa, and atopic dermatitis. This article discusses clinical trial data, real-world evidence, and guidelines and recommendations for biologics that inhibit tumor necrosis factor, interleukin (IL)-12/23, IL-17, IL-23, and IL-4/13 during the COVID-19 pandemic. Across these inflammatory skin conditions, existing data generally suggest that biologics do not seem to increase the risk of COVID-19 infection or worsen COVID-19 outcomes. The impact of biologics on COVID-19 is an area of active exploration.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Skin Diseases
/
Biological Products
/
COVID-19 Drug Treatment
Type of study:
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Dermatol Clin
Year:
2021
Document Type:
Article
Affiliation country:
J.det.2021.05.010
Similar
MEDLINE
...
LILACS
LIS